Ordaos is a biotechnology company using its proprietary generative AI platform, Apollo, to design novel mini-protein therapeutics for pharmaceutical partners. The platform accelerates drug discovery by enabling de novo identification of high-precision mini-proteins, significantly reducing time and cost compared to traditional approaches. The company is led by CEO David Longo. Lunch Pail Ventures invested in Ordaos in November 2024 and made a follow-on investment in July 2025.